Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMARTCARE pediatric asthma trial
ACTRN12623001339640Phase 3Recruiting
- Sponsor
- The University of Auckland
- Start
- Jan 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide + formoterol and salbutamol in asthma (2 arms), sponsored by The University of Auckland. Primary endpoint: Asthma exacerbations (moderate and severe) as rate per participant per year. Started Jan 2024; status: recruiting.
02
Drugs
budesonide + formoterolsalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12623001339640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001339640.